Ma Jia, Zhang Weizheng, Du Jia, Li Jiang, Lin Guangshuai, Tian Youfu
Department of Surgical Oncology, Shaanxi Provincial People's Hospital Xi'an 710068, Shaanxi, China.
Department of Surgical Oncology, Pucheng County Hospital Weinan 715500, Shaanxi, China.
Am J Transl Res. 2023 Feb 15;15(2):1485-1493. eCollection 2023.
To examine the safety and effectiveness of the combination of Camrelizumab and Abraxane + lobaplatin in advanced gastric cancer therapy.
The data of 60 patients with advanced gastric cancer in Shaanxi Provincial People's Hospital from May 2017 to March 2019 were analyzed retrospectively. The patients were divided into a study group (n=30) and a control group (n=30) according to different treatment methods. The study group received Camrelizumab combined with the Abraxane + lobaplatin regimen, and the control group received the Abraxane + lobaplatin regimen only. The levels of soluble interleukin-2 receptor (sIL-2R), secretory glycoprotein (Dickkopf-1, DKK-1) and tumor specific growth factors (TSGFs), the relative molecular expression of serum miRNA-1290, miRNA-647 and miRNA-182, and the Karnofsky performance status (KPS) were compared between the two groups. The adverse reactions of the two groups were observed, and the 3-year survival rates were compared.
The disease control rate and overall remission rate of the study group (53.33%, 90.00%) were higher than those of the control group (26.67%, 50.00%), with statistically significant differences (P<0.05). The levels of sLL-2R, DKK-1 and TSGF were reduced in both groups (.05) after being treated, whereas these were comparatively lower levels in the study group (P<0.05). After treatment, serum concentration of miRNA-1290, miRNA-647 and miRNA-182 were lower in the study group than in the control group (.05). Upon comparison with those in the control group, the KPS scores were higher at 1, 3 and 6 months after treatment in the study group (.05). The incidence of adverse events was not significantly different between the two groups (P>0.05). The 1-year, 2-year and 3-year survival rates were higher in the study group (57.38%, 39.34% and 29.51%) than in the control group (32.79%, 18.03% and 8.20%) (.05).
The combination of Camrelizumab and Abraxane + lobaplatin is an effective treatment for advanced gastric cancer and can increase the patient's survival rate.
探讨卡瑞利珠单抗联合白蛋白结合型紫杉醇+洛铂治疗晚期胃癌的安全性和有效性。
回顾性分析2017年5月至2019年3月陕西省人民医院60例晚期胃癌患者的数据。根据不同治疗方法将患者分为研究组（n=30）和对照组（n=30）。研究组接受卡瑞利珠单抗联合白蛋白结合型紫杉醇+洛铂方案，对照组仅接受白蛋白结合型紫杉醇+洛铂方案。比较两组可溶性白细胞介素-2受体（sIL-2R）、分泌型糖蛋白（Dickkopf-1，DKK-1）和肿瘤特异性生长因子（TSGFs）水平、血清miRNA-1290、miRNA-647和miRNA-182的相对分子表达以及卡氏功能状态（KPS）。观察两组的不良反应，并比较3年生存率。
研究组的疾病控制率和总缓解率（53.33%，90.00%）高于对照组（26.67%，50.00%），差异有统计学意义（P<0.05）。两组治疗后sLL-2R、DKK-1和TSGF水平均降低（P<0.05），而研究组这些水平较低（P<0.05）。治疗后，研究组血清miRNA-1290、miRNA-647和miRNA-182浓度低于对照组（P<0.05）。与对照组相比，研究组治疗后1、3和6个月时KPS评分更高（P<0.05）。两组不良事件发生率差异无统计学意义（P>0.05）。研究组的1年、2年和3年生存率（57.38%、39.34%和29.51%）高于对照组（32.79%、18.03%和8.20%）（P<0.05）。
卡瑞利珠单抗联合白蛋白结合型紫杉醇+洛铂是治疗晚期胃癌的有效方法，可提高患者生存率。
